Evidence map›Paper›PMID 37324199›Full record

ArticleRevista panamericana de salud publica = Pan American journal of public health2023

Moving toward improved access to medicines and health technologies for cardiovascular disease

Nora Giron, Christopher Lim, Juliana Vallini, Kemel Hallar

Open access · diamondAbstract read
In one paragraph

Article in Revista panamericana de salud publica = Pan American journal of public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Nora GironPan American Health Organization Washington, DC United States of America Pan American Health Organization, Washington, DC, United States of America.
Christopher LimPan American Health Organization Washington, DC United States of America Pan American Health Organization, Washington, DC, United States of America.
Juliana ValliniPan American Health Organization Washington, DC United States of America Pan American Health Organization, Washington, DC, United States of America.
Kemel HallarPan American Health Organization Washington, DC United States of America Pan American Health Organization, Washington, DC, United States of America.
World Health Organization Regional Office for the Americas · USClínica Girona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objectives of this article are to describe the interventions carried out by the Strategic Fund of the Pan American Health Organization to facilitate access to and availability of antihypertensive medicines and devices for measuring blood pressure across the Region of the Americas as part of the HEARTS initiative, and to present the preliminary results of price analyses of antihypertensive medicines. The study methodology included a review of reports made by the Strategic Fund between 2019 and 2020, an evaluation of modalities of procurement, a review of the public procurement databases for five antihypertensive medicines, and a comparison with the price obtained by the Strategic Fund. Differences in price ranging from 20% to 99% were identified, indicating significant opportunities for savings. The study also presents interprogrammatic actions that can support the HEARTS initiative, such as the inclusion of antihypertensive medicines recommended by the World Health Organization, consolidation of regional demand and competitively-priced long-term agreements to manage the procurement of quality generic products, and the definition of technical specifications and regulatory requirements to support the procurement of devices to measure blood pressure. This mechanism will enable Member States to reduce their costs significantly, while extending treatment and diagnostic coverage to more people.

Indexed as

Access to essential medicines and health technologiesantihypertensive agentsmedicine costStrategic Fund

Identifiers

PMID37324199
PMCPMC10261561
OpenAlexW4380303910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.